8-K: Cogent's Bezuclastinib Shines in GIST Phase 3 Trial

Cogent Biosciences announced highly positive Phase 3 PEAK trial results for bezuclastinib in imatinib-resistant GIST, showing significant progression-free survival and objective response rate benefits.

Summary

• Bezuclastinib in combination with sunitinib demonstrated a substantial and highly statistically significant clinical benefit in the PEAK Phase 3 Trial for imatinib-resistant or intolerant GIST patients.
• The combination reduced the risk of disease progression or death by 50% (hazard ratio of 0.50, 95% CI: 0.39 – 0.65) compared to sunitinib monotherapy.
• Median progression-free survival (PFS) was 16.5 months for the bezuclastinib combination versus 9.2 months for sunitinib monotherapy.
• The objective response rate (ORR) was 46% for the bezuclastinib combination compared to 26% for sunitinib.
• The combination was generally well tolerated, with no unique risks observed compared to sunitinib's known safety profile.
• The estimated mean duration of treatment for the bezuclastinib combination is projected to exceed 19 months.
• The company estimates a global annual market opportunity of over $4 billion for bezuclastinib in 2nd-line GIST, approximately $3 billion for non-advanced systemic mastocytosis (NonAdvSM), and approximately $500 million for advanced systemic mastocytosis (AdvSM), totaling over $7.5 billion.

Sentiment

Score: 9

Explanation: The Phase 3 trial results are overwhelmingly positive, demonstrating significant clinical benefit and a favorable safety profile for bezuclastinib in a high-unmet-need indication. The projected market opportunity is substantial, and the company has a clear regulatory path forward with multiple near-term catalysts. The only minor caveats are immature OS data and slightly higher rates of certain Grade 3+ AEs and discontinuations in the combination arm, which are common in oncology trials and appear manageable.

Positives

• Bezuclastinib combination reduced the risk of disease progression or death by 50% (HR 0.50, p<0.0001) in imatinib-resistant GIST patients.
• Median Progression-Free Survival (PFS) of 16.5 months for the combination significantly exceeded sunitinib monotherapy's 9.2 months.
• Achieved an unprecedented Objective Response Rate (ORR) of 46% with the combination, compared to 26% for sunitinib (p<0.0001).
• The bezuclastinib combination was generally well tolerated, with no unique safety risks identified compared to sunitinib.
• Projected mean duration of treatment for the bezuclastinib combination is over 19 months.
• Identified a global annual market opportunity of over $4 billion for bezuclastinib in 2nd-line GIST alone, with an aggregate potential across multiple indications exceeding $7.5 billion.
• Intellectual property protection for bezuclastinib is anticipated through 2043.
• An Expanded Access Program (EAP) is currently open, allowing immediate availability of the bezuclastinib combination for eligible 2nd-line GIST patients in the United States.

Negatives

• Overall survival data remains immature at the time of this analysis.
• Higher incidence of Grade 3+ ALT/AST increased (10.8% vs 1.4%) and Anemia (9.3% vs 4.8%) in the bezuclastinib combination arm compared to sunitinib monotherapy.
• 7.4% of patients on the bezuclastinib combination discontinued study treatment due to treatment-related adverse events, compared to 3.8% on sunitinib monotherapy.

Risks

• New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties.
• Actual results may differ materially from forward-looking statements due to various risks and uncertainties.
• Risks associated with the potential impacts of raising additional capital, including dilution to existing stockholders, restrictions on operations, or requirements to relinquish rights to technologies or product candidates.
• Business interruptions resulting from public health crises could disrupt product candidate development and adversely impact the business.
• Uncertainty regarding the success, cost, and timing of product development activities and clinical trials.
• Uncertainty regarding the timing of planned regulatory submissions to the FDA and feedback from the FDA.
• Inability to obtain and maintain regulatory approval for bezuclastinib and any other product candidates, and any related restrictions, limitations, and/or warnings in the label of an approved product candidate.
• Inability to license additional intellectual property relating to product candidates from third parties and to comply with existing license and collaboration agreements.
• Inability to obtain funding for operations, including funding necessary to complete further development and commercialization of product candidates.
• Challenges with the scalability and commercial viability of manufacturing methods and processes.
• Risks related to the commercialization of product candidates, if approved.
• Inability to attract collaborators with development, regulatory, and commercialization expertise.
• Challenges in obtaining and maintaining intellectual property protection for product candidates.
• Interim clinical data may not be indicative of future results.

Future Outlook

The company plans to submit a New Drug Application (NDA) for bezuclastinib in NonAdvSM patients by the end of 2025 and for imatinib-resistant GIST patients in the first half of 2026. Full PEAK results will be presented at a scientific conference in the first half of 2026. The company expects the bezuclastinib plus sunitinib combination to become the new standard of care for second-line GIST patients, with a projected mean treatment duration exceeding 19 months. Top-line results from the APEX trial are expected in December 2025, and multiple bezuclastinib presentations, including initial data from a novel JAK2 V617F inhibitor, are planned for the 2025 ASH meeting.

Management Comments

• We believe Peak results are transformative and practice changing.
• Bezuclastinib combination establishes first new benchmark for 2L GIST in 20 years.
• The Company believes bezuclastinib represents a significant commercial opportunity across multiple indications.
• The bezuclastinib plus sunitinib combination is poised to become the new standard of care for second line GIST patients.

Industry Context

The results for bezuclastinib + sunitinib represent the first new benchmark for second-line GIST in 20 years, addressing a significant unmet medical need where current approved agents (sunitinib, regorafenib, ripretinib) offer modest historical performance and are effective against only subsets of resistance mutations. The combination's ability to inhibit a full spectrum of primary and secondary KIT mutations positions it as a potentially superior treatment option compared to existing TKIs that do not inhibit all mutations.

Comparison to Industry Standards

• Bezuclastinib + Sunitinib achieved a median Progression-Free Survival (PFS) of 16.5 months, significantly outperforming Sunitinib monotherapy (9.2 months in this trial, 5.5 months in USPI benchmarks).
• The Objective Response Rate (ORR) of 46% for Bezuclastinib + Sunitinib is unprecedented in imatinib-resistant patients, compared to Sunitinib's 26% in this trial and historical benchmarks of ~7% for Sunitinib, ~5% for Regorafenib, and ~9% for Ripretinib.
• The combination's 50% reduction in risk of disease progression or death sets a new standard compared to current standard of care.
• The safety profile is generally consistent with sunitinib alone, indicating no unique risks with the novel combination, which is favorable compared to the known adverse event profiles of existing TKIs.

Stakeholder Impact

• Shareholders: Highly positive news likely to increase investor confidence and potentially share price due to successful Phase 3 trial, large market opportunity, and clear path to regulatory submissions.
• Patients (GIST): Offers a new, significantly more effective treatment option for imatinib-resistant or intolerant GIST, addressing a high unmet medical need.
• Healthcare Providers: Provides a new potential standard of care for second-line GIST, offering improved patient outcomes.
• Employees: Positive trial results and commercial prospects could lead to increased job security and potential growth opportunities.

Next Steps

• Present detailed PEAK Phase 3 data results at a major medical conference in the first half of 2026.
• Announce top-line results from the pivotal APEX trial in Advanced Systemic Mastocytosis (AdvSM) in December 2025.
• Present multiple bezuclastinib presentations at the 67th Annual Meeting of the American Society of Hematology (ASH), including two oral presentations from the pivotal SUMMIT trial in NonAdvSM patients.
• Present initial data from the company's novel JAK2 V617F inhibitor at ASH.
• Submit the first New Drug Application (NDA) for bezuclastinib in NonAdvSM patients by the end of 2025.
• Submit NDA for bezuclastinib in imatinib-resistant or intolerant GIST patients in the first half of 2026.

Key Dates

Recommendation

The highly positive Phase 3 PEAK trial results for bezuclastinib in GIST demonstrate a significant clinical advantage over the current standard of care, including a 50% reduction in disease progression risk and a substantial increase in median PFS and ORR. This positions bezuclastinib as a potential new standard of care in a market with high unmet need and a multi-billion dollar annual opportunity. Coupled with a generally favorable safety profile, a clear regulatory submission timeline, and additional pipeline catalysts (APEX, SUMMIT, JAK2 V617F inhibitor), the company exhibits strong growth potential. The intellectual property protection through 2043 further solidifies its market position. These factors collectively indicate a compelling investment opportunity.

Keywords

Bezuclastinib, GIST, Gastrointestinal Stromal Tumors, Phase 3, PEAK trial, Sunitinib, Imatinib-resistant, Progression-Free Survival, Objective Response Rate, Oncology, Cancer, Clinical Trial, Biotech, Pharmaceutical, FDA, NDA, Systemic Mastocytosis, KIT inhibitor